Valuation: AFT Pharmaceuticals Limited

Market Cap 389M 221M 194M 178M 166M 315M 21.1B 319M 2.14B 831M 10.36B 831M 812M 35.91B P/E 2027 *
19.7x
P/E 2028 * 15.7x
Enterprise Value 419M 238M 209M 192M 178M 339M 22.72B 343M 2.3B 895M 11.15B 894M 875M 38.66B EV / Sales 2027 *
1.38x
EV / Sales 2028 * 1.2x
Free-Float
22.37%
Yield 2027 *
0.88%
Yield 2028 * 1.12%
Manager TitleAgeSince
Human Resources Officer - 2012-09-03
Chief Executive Officer - 1997-09-03
Director of Finance/CFO - 2026-06-14
Director TitleAgeSince
Chairman - 2015-06-21
Director/Board Member - 1997-09-03
Director/Board Member - 2012-09-03
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 221M
-1.14%-2.43%+53.72%+159.07% 1,082B
-1.41%+0.32%+66.23%+60.48% 633B
-2.42%+0.18%+34.59%+85.62% 461B
-0.26%+0.53%+31.00%+25.82% 338B
-2.46%-1.38%+36.42%+36.52% 299B
-2.20%-0.87%+27.50%+42.69% 291B
-1.77%+1.97%-28.85%-40.66% 222B
-2.06%+1.63%+22.87%+64.34% 202B
-1.26%+2.60%+15.98%+70.00% 163B
Average -1.50%+0.62%+28.83%+55.99% 410.27B
Weighted average by Cap. -1.55%-0.22%+39.61%+80.57%

Financials

2027 *2028 *
Net sales 304M 173M 151M 139M 129M 246M 16.48B 249M 1.67B 649M 8.09B 649M 635M 28.05B 345M 196M 172M 158M 147M 279M 18.73B 283M 1.9B 738M 9.19B 737M 721M 31.87B
Net income 19.71M 11.21M 9.81M 9.04M 8.39M 15.93M 1.07B 16.15M 108M 42.11M 525M 42.08M 41.16M 1.82B 24.84M 14.12M 12.37M 11.39M 10.57M 20.08M 1.35B 20.35M 136M 53.07M 661M 53.03M 51.87M 2.29B
Net Debt 29.84M 16.97M 14.86M 13.69M 12.7M 24.12M 1.62B 24.45M 164M 63.76M 794M 63.71M 62.31M 2.75B 24.59M 13.98M 12.24M 11.28M 10.47M 19.88M 1.33B 20.15M 135M 52.54M 655M 52.5M 51.35M 2.27B
Logo AFT Pharmaceuticals Limited
AFT Pharmaceuticals Limited is a New Zealand-based multinational pharmaceutical company. The Company develops, markets, and distributes a portfolio of pharmaceutical products across a range of therapeutic categories, which are distributed across three pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Its product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs. The Company develops and in-licenses products for sale by sales teams in Australia and New Zealand and in certain Southeast Asian markets, and out-licenses its products to local licensees and distributors in the rest of the world. Its products include A-Scabies, Allersoothe, Allersoothe Elixir, BecloClear, Candaderm, Coco-Scalp, Cromo-Fresh, Fenpaed, Fenpaed Double Strength, Ferro-Sachets, HYLO-FORTE, Itch-Soothe, Kiwisoothe, Lax-Tab, Loraclear, VitA-POS, and others.
Employees
126
Trader
Investor
Global
Quality
ESG MSCI
-